{"url_path":"/sec/mbot/8-k/2026-06-02/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-02","source_url":"https://www.sec.gov/Archives/edgar/data/883975/0001493152-26-026769-index.html","accession_number":"0001493152-26-026769","cik":"0000883975","ticker":"MBOT","issuer_name":"Microbot Medical Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/883975/0001493152-26-026769-index.html","primary_entity_key":"0000883975","primary_entity_name":"Microbot Medical Inc."},"word_count":139,"has_tables":true,"body_markdown":"** **\n\n**Item\n7.01 Regulation FD Disclosure.**\n\n \n\nOn\nJune 2, 2026, Microbot Medical Inc. (the “Company”) issued a press release announcing that it has secured its first North\nCarolina-based customer, becoming the latest healthcare system to adopt the LIBERTY® Endovascular Robotic System, demonstrating\na broadening geographic penetration from the southeast, mid-Atlantic and northeast U.S.\n\n \n\nThe\npress release, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K, is incorporated herein by reference. The information\nin this Item 7.01 and Exhibit 99.1 is being furnished and shall not be deemed to be “filed” for the purposes of Section 18\nof the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be\ndeemed an admission as to the materiality of any information in this Item 7.01 or Exhibit 99.1."}